Evidence map›Paper›PMID 31969883›Full record

ArticleFrontiers in immunology2019

Optimization of

Rachelle P Davis, Bas G J Surewaard, Madison Turk, Agostina Carestia, Woo-Yong Lee, Björn Petri, Stefan J Urbanski, Carla S Coffin, Craig N Jenne

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Intrahepatic Platelets Orchestrate Microenvironmental Remodelling and Cellular Crosstalk in Liver Fibrosis.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Comparisons of 3D printed materials for biomedical imaging applications.Science and technology of advanced materials · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Intravital Imaging of Inflammatory Response in Liver Disease.Frontiers in cell and developmental biology · 2022
    Review
  10. Intravital Microscopy Techniques to Image Wound Healing in Mouse Skin.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  11. Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPAREvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Rachelle P DavisDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, AB, Canada.
Bas G J SurewaardDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, AB, Canada.
Madison TurkDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, AB, Canada.
Agostina CarestiaDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, AB, Canada.
Woo-Yong LeeSnyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada.
Björn PetriDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, AB, Canada.
Stefan J UrbanskiDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
Carla S CoffinDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, AB, Canada.
Craig N JenneDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, AB, Canada.
University of Calgary · CA

Funding

CIHR
6 · The paper itself

Abstract

Non-alcoholic fatty liver disease is a spectrum of liver pathology ranging from simple steatosis to steatohepatitis and can progress to diseases associated with poor outcomes including cirrhosis and hepatocellular carcinoma (HCC). NAFLD research has typically focused on the pathophysiology associated with lipid metabolism, using traditional measures such as histology and serum transaminase assessment; these methods have provided key information regarding NAFLD progression. Although valuable, these techniques are limited in providing further insight into the mechanistic details of inflammation associated with NAFLD. Intravital microscopy (IVM) is an advanced tool that allows for real-time visualization of cellular behavior and interaction in a living animal. Extensive IVM imaging has been conducted in liver, but, in the context of NAFLD, this technique has been regularly avoided due to significant tissue autofluorescence, a phenomenon that is exacerbated with steatosis. Here, we demonstrate that, using multiple imaging platforms and optimization techniques to minimize autofluorescence, IVM in fatty liver is possible. Successful fatty liver intravital imaging provides details on cell trafficking, recruitment, function, and behavior in addition to information about blood flow and vessel dynamics, information which was previously difficult to obtain. As more than 30% of the global population is overweight/obese, there is a significant proportion of the population at risk for NAFLD and complications due to NAFLD (liver decompensation, cirrhosis, HCC). IVM has the potential to elucidate the poorly understood mechanisms surrounding liver inflammation and NAFLD progression and possesses the potential to identify key processes that may be targeted for future therapeutic interventions in NAFLD patients.

Indexed as

Intravital MicroscopyAnimalsCell TrackingDisease Models, AnimalDisease ProgressionFluorescent Antibody TechniqueImmunohistochemistryMiceNon-alcoholic Fatty Liver DiseasePhenotypefatty liverintravital imagingmiceNAFLDtechnique

Identifiers

PMID31969883
PMCPMC6960139
OpenAlexW3000402533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.